Crinetics Pharmaceuticals, Inc.
CRNX
$35.70
-$0.35-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.93% | -52.24% | -43.05% | -39.41% | -39.10% |
| Total Depreciation and Amortization | 39.68% | 63.08% | 95.35% | 151.05% | 153.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.58% | 33.92% | 36.69% | 44.55% | 48.46% |
| Change in Net Operating Assets | -34.66% | -138.07% | -130.10% | -142.18% | -7.87% |
| Cash from Operations | -64.18% | -74.34% | -68.56% | -48.95% | -38.42% |
| Capital Expenditure | -49.90% | -68.88% | 10.77% | 37.52% | 18.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.47% | -260.28% | -72.21% | -170.67% | -191.72% |
| Cash from Investing | 130.25% | -254.30% | -70.54% | -165.65% | -186.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.06% | 11.03% | -23.12% | -24.19% | 150.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 105.73% | 98.57% | 105.79% | 34.10% |
| Cash from Financing | -96.00% | 15.00% | -19.55% | -20.01% | 160.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.99% | -218.28% | -194.60% | -184.95% | 843.34% |